EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Studying the Humoral Response against SARS‐CoV‐2 in Cuban COVID‐19 Recovered Patients

Ivette Orosa Vázquez, Marianniz Díaz, Yaima Zúñiga Rosales, Klayris Amada, Janoi Chang, Ernesto Relova Hernández, Yaima Tundidor, Hilda Roblejo Balbuena, Giselle Monzón, Bárbara Torres Rives, Enrique Noa Romero, Danay Carrillo Valdés und 9 weitere

Journal of Immunology Research · 2024

DOI: 10.1155/2024/7112940 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Immunology Research, 2024. Verfasst von Ivette Orosa Vázquez und 20 weiteren Autor:innen. Beteiligte Einrichtung: Center of Molecular Immunology, 15th Avenue and 216 Street, Siboney, Playa, Havana, Cuba. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Antibodies, Viral, Immunoglobulin G. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Understanding the immune response generated by SARS‐CoV‐2 is critical for assessing efficient therapeutic protocols and gaining insights into the durability of protective immunity. The current work was aimed at studying the specific humoral responses against SARS‐CoV‐2 in Cuban COVID‐19 convalescents. We developed suitable tools and methods based on ELISA methodology, for supporting this evaluation. Here, we describe the development of an ELISA for the quantification of anti‐RBD IgG titers in a large number of samples and a similar test in the presence of NH 4 SCN as chaotropic agent for estimating the RBD specific antibody avidity. Additionally, a simple and rapid ELISA based on antibody‐mediated blockage of the binding RBD‐ACE2 was implemented for detecting, as a surrogate of conventional test, the levels of anti‐RBD inhibitory antibodies in convalescent sera. In a cohort of 273 unvaccinated convalescents, we identified higher anti‐RBD IgG titer (1 : 1,330, p < 0.0001) and higher levels of inhibitory antibodies blocking RBD‐ACE2 binding (1 : 216, p < 0.05) among those who had recovered from severe illness. Our results suggest that disease severity, and not demographic features such as age, sex, and skin color, is the main determinant of the magnitude and neutralizing ability of the anti‐RBD antibody response. An additional paired longitudinal assessment in 14 symptomatic convalescents revealed a decline in the antiviral antibody response and the persistence of neutralizing antibodies for at least 4 months after the onset of symptoms. Overall, SARS‐CoV‐2 infection elicits different levels of antibody response according to disease severity that declines over time and can be monitored using our homemade serological assays.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2Antibodies, ViralImmunoglobulin GImmunity, HumoralEnzyme-Linked Immunosorbent AssayAntibodies, NeutralizingHumansCubaMaleFemaleMiddle AgedAdultSpike Glycoprotein, CoronavirusAgedAngiotensin-Converting Enzyme 2Antibody Affinity

Substanzen

Antibodies, ViralImmunoglobulin GAntibodies, NeutralizingSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Angiotensin-Converting Enzyme 2ACE2 protein, human

Autor:innen und Institutionen

  • Center of Molecular Immunology, 15th Avenue and 216 Street, Siboney, Playa, Havana, Cuba.
  • National Center of Medical Genetics, 31st Avenue, N°3102 and 146 Street, Cubanacán, Playa, Havana, Cuba.
  • Julio Trigo Hospital, km 7½ Calzada de Bejucal, Diez de Octubre, Havana, Cuba.
  • Research Center of Civil Defense, José de las Lajas, San, Mayabeque, Cuba.
  • Centre for Immunoassays, 134st. And 25, Cubanacán, Playa, Havana, Cuba.

ORCID-Profile: Tania Carmenate

Zitieren

APA

Orosa Vázquez, I., Díaz, M., Zúñiga Rosales, Y., Amada, K., Chang, J., Relova Hernández, E., Tundidor, Y., Roblejo Balbuena, H., Monzón, G., Torres Rives, B., Noa Romero, E., Carrillo Valdés, D., Valdivia Álvarez, I., Delahanty Fernández, A., Díaz, C., Solozabal, J., Gil, M., Sánchez, B., Rojas, G., …, & Carmenate, T. (2024). Studying the Humoral Response against SARS‐CoV‐2 in Cuban COVID‐19 Recovered Patients. Journal of Immunology Research. https://doi.org/10.1155/2024/7112940

Vancouver

Orosa Vázquez I, Díaz M, Zúñiga Rosales Y, Amada K, Chang J, Relova Hernández E, et al. Studying the Humoral Response against SARS‐CoV‐2 in Cuban COVID‐19 Recovered Patients. Journal of Immunology Research. 2024. doi:10.1155/2024/7112940

BibTeX
@article{OrosaVzquez2024,
  author = {Orosa Vázquez, Ivette and Díaz, Marianniz and Zúñiga Rosales, Yaima and Amada, Klayris and Chang, Janoi and Relova Hernández, Ernesto and Tundidor, Yaima and Roblejo Balbuena, Hilda and Monzón, Giselle and Torres Rives, Bárbara and Noa Romero, Enrique and Carrillo Valdés, Danay and Valdivia Álvarez, Irinia and Delahanty Fernández, Aurora and Díaz, Claudia and Solozabal, Joaquín and Gil, Mileidys and Sánchez, Belinda and Rojas, Gertrudis and Marcheco, Beatriz and Carmenate, Tania},
  title = {Studying the Humoral Response against SARS‐CoV‐2 in Cuban COVID‐19 Recovered Patients},
  journal = {Journal of Immunology Research},
  year = {2024},
  doi = {10.1155/2024/7112940}
}
Kostenlos starten →